While the PARP inhibitor talazoparib in combination with enzalutamide is FDA approved for the treatment of select patients with ATR-mutant metastatic castration-resistant prostate cancer, no ATR-targeted therapy for pancreatic cancer was identified in the OncoKB database [32]. The gene discussed is ATR; the disease is familial pancreatic carcinoma.